Company
Novartis AG (ADR)
NYSE:NVS
Novartis provides healthcare solutions that address the evolving needs of patients and societies.
44 stories · page 1 of 3
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial
Novartis AG (ADR) (NYSE:NVS) shares fell as much as 10% after the company's del-desiran failed to meet the primary endpoint in its pivotal Phase 3 HARBOR...
Dow closes sharply lower as oil surge fuels inflation fears
4:15pm: Oil spike hits stocks US stocks closed sharply lower on Tuesday as surging oil prices revived inflation worries and pushed investors to reassess the...
Novartis to axe 8,000 jobs, some will be transferred to India
Vas Narasimhan, the company's chief executive projected job cuts in the "single-digit thousands" as part of a restructuring programme announced in April, aiming to save US$1bn by 2024
Tarus Therapeutics beefs up its board of directors with a pair of pharmaceutical industry veterans
The firm added David Epstein, the former CEO of Novarits Pharmaceuticals, and David Nicholson, who has served in leadership roles at Allergan, Bayer CropScience and elsewhere
Aequus Pharma’s sales push expands market for revenue-drivers Tacrolimus and Vistitan
CEO Doug Janzen says the long-term revenue potential for both drugs remains high after final royalty adjustments with Sandoz
Investments and investor services
IPO Roundup: Rattler Midstream holds steady after its debut; Bicycle Therapeutics off to a wobbly start
Two cancer biotechnology companies made their debuts along with a Texas oil company
Investments and investor services
IPO Roundup: Peloton Therapeutics gobbled up by Merck just as it prepared to go public
The sale provides Peloton shareholders with $1.05 billion in cash, with a possible $1.15 more if its treatments hit certain milestones